ScreenerHero

ADXN Addex Therapeutics Ltd

SWX · CH · Healthcare · Biotechnology · addextherapeutics.com
0.0230CHF+3.60%Mkt Cap: 5.52M $P/E: —

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enz…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated - Common Stock
$127.85BUSDP/E 29.4
MRNA
Moderna, Inc. - Common Stock
$75.86BUSD
REGN
Regeneron Pharmaceuticals, Inc. - Common Stock
$75.69BUSDP/E 18.2
ARGX
argenx SE - American Depositary Shares
$57.51BUSDP/E 35.1
ARGX
argenx SE
$55.24BUSDP/E 36.1
RVMD
Revolution Medicines, Inc. - Common Stock
$44.29BUSD
UCB
UCB SA
$41.63BUSDP/E 17.7
ONC
BeOne Medicines Ltd. - American Depositary Shares
$40.51BUSDP/E 63.9
RPRX
Royalty Pharma plc - Class A Ordinary Shares
$33.03BUSDP/E 30.7
ALNY
Alnylam Pharmaceuticals, Inc. - Common Stock
$29.40BUSDP/E 38.3
ROIV
Roivant Sciences Ltd. - Common Shares
$25.80BUSD
BNTX
BioNTech SE - American Depositary Shares
$24.34BUSD
INSM
Insmed Incorporated - Common Stock
$24.27BUSD
INCY
Incyte Corporation - Common Stock
$23.37BUSDP/E 14.7
GMAB
Genmab A/S
$21.61BUSDP/E 29.3
GMAB
Genmab A/S - American Depositary Shares
$21.69BUSDP/E 27.4
JAZZ
Jazz Pharmaceuticals plc - Ordinary Shares
$15.30BUSDP/E 16.1
ASND
Ascendis Pharma A/S - Ordinary Share
$14.99BUSDP/E 17.8
EXEL
Exelixis, Inc. - Common Stock
$14.47BUSDP/E 18.4
SMMT
Summit Therapeutics Inc. - Common Stock
$13.37BUSD

Key Statistics

Company
Market Cap5.52M USD
Enterprise Value3.63M USD
Revenue (TTM)94.81K USD
Gross Profit-310.64K USD
Net Income (TTM)-7.68M USD
Revenue/Share0.0010 CHF
Last Price0.0230 CHF
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees3
CountryCH
SectorHealthcare
IndustryBiotechnology
ISINCH0029850754
Valuation
P/E (Trailing)—
P/E (Forward)-0.56
PEG—
EV/EBITDA-1.22
EV/Revenue38.32
P/S56.20
P/B2.02
EPS (TTM)-0.05
EPS (Forward)-0.04
52W Range
0.018010% of range0.0690
52W High0.0690 CHF
52W Low0.0180 CHF
Profitability
Gross Margin0.00%
Oper. Margin-6487.25%
EBITDA Margin0.00%
Profit Margin-22448.44%
ROE-141.15%
ROA-105.72%
Growth
Revenue Growth-72.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-2.48M USD
CapEx (TTM)—
FCF Margin-1726.17%
FCF Yield-29.65%
Net Debt-787.31K USD
Net Debt/EBITDA0.26
Balance Sheet
Debt/Equity0.01
Current Ratio0.76
Quick Ratio0.58
Book Value/Sh0.01 CHF
Cash/Share0.0040 CHF
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 CHF
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateJul 26, 2022
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.210.29M
Float141.93M
Insiders10.00%
Institutions1.04%
Technical
SMA 500.0309 (-25.7%)
SMA 2000.0429 (-46.4%)
Beta—
S&P 52W Chg14.58%
Avg Vol (30d)1.03M
Avg Vol (10d)1.02M
Technical Indicators
RSI (14)36.8
MACD-0.0026
MACD Signal-0.0030
MACD Hist.+0.0004
BB Upper0.0269 CHF
BB Middle0.0233 CHF
BB Lower0.0198 CHF
BB Width30.17%
ATR (14)0.0036 CHF
Vol Ratio (20d)2.00x